Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 4/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19714858 | 0.85 | PDPK1 (0.40) | PDPK1JAK1JAK2GPR119 | |
| SCHEMBL19714874 | 0.85 | JAK1 (0.36) | PDPK1JAK1KDM1AJAK2 | |
| SCHEMBL19730197 | 0.79 | KDM1A (0.40) | KDM1ASYK | |
| SCHEMBL19730196 | 0.72 | HTR6 (0.36) | PDPK1 | |
| SCHEMBL19715023 | 0.72 | PDPK1 (0.36) | PDPK1 | |
| SCHEMBL20049565 | 0.69 | PDPK1 (0.39) | PDPK1JAK1JAK2GPR119 | |
| SCHEMBL13759623 | 0.68 | GPR119 (0.33) | PDPK1GPR119 | |
| SCHEMBL25047944 | 0.66 | PIP4K2A (0.44) | KDM1A | |
| SCHEMBL19714842 | 0.66 | ADCY5 (0.48) | — | |
| SCHEMBL21176120 | 0.66 | CHKA (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | PDPK1 1535/4885JAK1 3521/4885KDM1A 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.